Was Bristol-Myers Squibb’s assay to blame for Opdivo’s first-line lung flop?
admin 22nd June 2017 Uncategorised 0Full results from Bristol-Myers Squibb’s infamous Opdivo monotherapy trial in first-line lung cancer are finally out—alongside a theory about why that trial came up short. Some analysts, though, aren’t buying the new hypothesis.
More: Was Bristol-Myers Squibb’s assay to blame for Opdivo’s first-line lung flop?
Source: fierce